Immunotherapy against several tumors including gastrointestinal and gastric cancer

Patent metadata

Field	Value
Publication number	US-9895415-B2
Application number	US-201715636958-A
Country	US
Kind code	B2
Filing date	Jun 29, 2017
Priority date	Mar 19, 2010
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

A method of treating a patient who has gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer. A method of treating a patient who has gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the gastric cancer.

First claim

The invention claimed is:

1. A method of treating a patient who has gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide comprises an amino acid sequence selected from the group consisting of SYLQAANAL (SEQ ID NO: 23), FLLDGSANV (SEQ ID NO: 68), NLLDLDYEL (SEQ ID NO: 69), and FLIDSSEGV (SEQ ID NO: 70), wherein the peptide is in a complex with an MHC molecule.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , further comprising expanding T cells in vitro.

6. The method of claim 1 , wherein the MHC molecule is a class I molecule.

7. The method of claim 1 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG, oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with PLG and virosomes.

9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.

10. The method of claim 9 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and 11-12 to clonally expand the T cells.

11. A method of treating a patient who has gastric cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide comprises an amino acid sequence selected from the group consisting of SYLQAANAL (SEQ ID NO: 23), FLLDGSANV (SEQ ID NO: 68), NLLDLDYEL (SEQ ID NO: 69), and FLIDSSEGV (SEQ ID NO: 70), thereby inducing a T-cell response to the cancer.

12. The method of claim 11 , wherein the composition further comprises an adjuvant.

13. The method of claim 11 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG, oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, and particulate formations with PLG and virosomes.

14. The method of claim 11 , wherein the T cell response is a cytotoxic T cell response.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Fritsche Jens
• Weinschenk Toni
• Walter Steffen
• Lewandrowski Peter
• Singh Harpreet

Classifications

• A61K38/1709 Primary

  from mammals · CPC title

• C07K7/06 Primary

  having 5 to 11 amino acids · CPC title

• G01N33/505

  involving T-cells · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61K2039/585

  wherein the target is cancer · CPC title